Patent · US Active

Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response

US11730810B2 · kind B2 · utility

0Cited by
5References
26Claims
0Family size

Assignees

Inventors

Key dates

Filing dateNov 14, 2018
Grant dateAug 22, 2023
Priority date
Expiry dateOct 20, 2039

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are imidazopyrimidine compounds, such as compounds of Formula (I), for use in enhancing human immune response and/or as adjuvants in vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.